Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec 10;15(2):73-78.
doi: 10.17925/HI.2021.15.2.73. eCollection 2021.

An Update on Drug-eluting Technology in Peripheral Arteries to Treat Peripheral Arterial Disease

Leonardo Marques  1 , Silke Hopf-Jensen  1 , Michael Preiss  1 , Stefan Mueller-Huelsbeck  1
Affiliations
Review

An Update on Drug-eluting Technology in Peripheral Arteries to Treat Peripheral Arterial Disease

Leonardo Marques et al. Heart Int. .

Abstract

For the treatment of peripheral arterial disease, drug-eluting technology is a widely accepted therapeutic option, with significant reduction in intimal hyperplasia and, consequently, use of target lesion revascularization. Nevertheless, the reputation of such devices was damaged after a meta-analysis, published in December 2018, showed increased mortality in patients receiving paclitaxel-eluting devices. Although subsequent studies have failed to establish such correlation, the use of paclitaxel-eluting devices remains heavily restricted. As such, other options and drugs have been developed, for instance sirolimus. In this article we present the available data on drug-eluting technology.

Keywords: Paclitaxel; drug-coated balloon; drug-eluting stents; drug-eluting technology; peripheral arterial disease; sirolimus.

PubMed Disclaimer

Conflict of interest statement

Disclosures: Leonardo Marques, Silke Hopf-Jensen, Michael Preiss and Stefan Mueller-Huelsbeck have no financial or non-financial relationships or activities to declare in relation to this article.

Figures

Figure 1:
Figure 1:. Results from several studies on clinically driven target lesion revascularization and mean lesion length at 12 months,,,,–
See this image and copyright information in PMC

References

    1. Moses J, Leon M, Popma J. et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–23. - PubMed
    1. Piccolo R, Bonaa K, Efthimiou O. et al. Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials. Lancet. 2019;393:2503–10. - PubMed
    1. Baerlocher MO, Kennedy SA, Rajebi MR. et al. Meta-analysis of drug-eluting balloon angioplasty and drug-eluting stent placement for infrainguinal peripheral arterial disease. J Vasc Interv Radiol. 2015;26:459–73. - PubMed
    1. Zeller T, Baumgartner I, Scheinert D. et al. Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial. J Am Coll Cardiol. 2014;64:1568–76. - PubMed
    1. Klumb C, Lehmann T, Aschenbach R. et al. Benefit and risk from paclitaxel-coated balloon angioplasty for the treatment of femoropopliteal artery disease: a systematic review and meta-analysis of randomised controlled trials. EClinicalMedicine. 2019;16:42–50. - PMC - PubMed

LinkOut - more resources